Page 1

First - Quarter 2021 First Quarter Overall Net Sales $ 670.7M | 36.5 % Diluted Earnings Per Share : $ 1.99 | 101 % Adjusted Diluted Earnings Per Share : $ 2.05 1103 % " We delivered another solid performance in the first - quarter with strong organic sales growth coming from both our base business as well as increased demand for our products associated with COVID - 19 vaccines . I am proud of the relentless focus and consistent execution of our global team members to deliver critical components and solutions during these times . With a strong start to the year , we are raising our full - year financial guidance . West will continue to play an integral role with our customers as they develop and bring new medicines to the market for a brighter future . " Eric M. Green President and Chief Executive Officer West Pharmaceutical Services , Inc. OVERALL ORGANIC SALES GROWTH Proprietary Products Q1 2021 organic sales growth of 39.6 % , led by sales of high - value products , which grew double digits P BIOLOGICS GENERICS PHARMA CONTRACT MANUFACTURING West Q1 31.1 % DD DD DD MSD Abbreviations : LSD - low - single digit ; MSD - mid - single digit ; HSD -high - single digit ; DD - double digit Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain " forward - looking statements " as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include , but are not limited to , statements about product development and operational performance . Each of these statements is based on preliminary information , and actual results could differ from any preliminary estimates . We caution investors that the risk factors listed under " Cautionary Statement " in our press releases , as well as those set forth under the caption " Risk Factors " in our most recent Annual Report on Form 10 - K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10 - Q , could cause our actual results to differ materially from those estimated or predicted in the forward - looking statements . You should evaluate any statement in light of these important factors . Except as required by law or regulation , we undertake no obligation to publicly update any forward - looking statements , whether as a result of new information , future events , or otherwise . Non - U.S . GAAP Financial Measures Certain financial measures included in these presentation materials , or which may be referred to in management's discussion of the Company's results and outlook , have not been calculated in accordance with US . generally accepted accounting principles ( " US . GAAP " ) , and therefore are referred to as non U.S. GAAP financial measures . Non - U.S . GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP . Please refer to " Reconciliation of Non - US . GAAP Financial Measures " at the end of these materials for more information . WST Q1 2021 Earnings 1